The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s research includes a study on a targeted therapy combination for treating low-grade childhood glioma with a BRAF V600 mutation. Read More >>
targeted therapy
June 6, 2022 · Brielle Gregory Collins, ASCO staff
June 5, 2022 · Leslie Fannon Zhang, ASCO staff
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include advances in treating HER2-low metastatic breast cancer, RAS wild-type metastatic colorectal cancer, recurrent and refractory Ewing sarcoma, and newly diagnosed multiple myeloma. Read More >>
June 4, 2022 · Brielle Gregory Collins, ASCO staff
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include targeted therapy for advanced hormone receptor-positive, HER2-negative breast cancer and using liquid biopsy to guide post-surgery treatment decisions for stage II colon cancer. Read More >>
June 3, 2022 · Greg Guthrie, ASCO staff
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma. Read More >>
February 3, 2022 · Brielle Gregory Collins, ASCO staff
In this podcast, Dr. Christopher Flowers discusses research from the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, including studies evaluating new treatments for diffuse large B-cell lymphoma and an overview of a session on improving equity in cancer clinical trials. Read More >>